Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Chasan-Taber, L.    Stampfer, M. J.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Epidemiology of Oral Contraceptives and Cardiovascular Disease

Lisa Chasan-Taber, ScD, and Meir J. Stampfer, MD

15 March 1998 | Volume 128 Issue 6 | Pages 467-477

Purpose: To review the association between combined oral contraceptives and cardiovascular disease, with emphasis on oral contraceptives containing low doses of estrogen (low-dose oral contraceptives).

Data Sources: A systematic search of the MEDLINE database was done for all relevant articles published between 1967 (when low-dose oral contraceptives were introduced in the United States) and June 1997. Textbooks, meeting proceedings, and reference lists were also searched.

Study Selection: All English-language human epidemiology studies of oral contraceptives that used cardiovascular disease as an end point were reviewed. Animal and metabolic studies were reviewed only if they were especially relevant to the mechanism of action of oral contraceptives.

Data Extraction: Descriptive and analytic data from each study were collected.

Data Synthesis: Data were organized by cardiovascular end point, study design, estrogen dose, and type of progestogen. Data on relative and absolute risk are presented to address current prescription guidelines.

Conclusions: The risk for cardiovascular disease is lower with current preparations of oral contraceptives, including those that contain the new progestogens, than with older oral contraceptives containing high doses of estrogen. Among users of low-dose oral contraceptives, cardiovascular diseases occur mainly in smokers and women with predisposing factors. Every effort should be made to encourage smoking cessation among potential users of oral contraceptives.

Author and Article Information

From Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts.
Acknowledgments: The authors thank Rachel Adams and Stephanie Parker for technical assistance.
Grant Support: In part by a consulting agreement with Ortho Pharmaceuticals.
Requests for Reprints: Lisa Chasan-Taber, ScD, Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, 420 Arnold House, University of Massachusetts, Amherst, MA 01003.
Current Author Addresses: Dr. Chasan-Taber: Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, 420 Arnold House, University of Massachusetts, Amherst, MA 01003.

This article has been cited by other articles:

				B. A. Frempong, M. Ricks, S. Sen, and A. E. Sumner Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2097 - 2103. [Abstract] [Full Text] [PDF]

				L. A. Kroon Drug interactions with smoking Am. J. Health Syst. Pharm., September 15, 2007; 64(18): 1917 - 1921. [Abstract] [Full Text] [PDF]

				M. Luque-Ramirez, F. Alvarez-Blasco, J. I. Botella-Carretero, E. Martinez-Bermejo, M. A. Lasuncion, and H. F. Escobar-Morreale Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate Versus Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2453 - 2461. [Abstract] [Full Text] [PDF]

				V. Bittner Perspectives on Dyslipidemia and Coronary Heart Disease in Women J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1628 - 1635. [Abstract] [Full Text] [PDF]

				J. A. Heit The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism Chest, September 1, 2003; 124(3_suppl): 40S - 48S. [Abstract] [Full Text] [PDF]

				P. Hannaford, J. P. Vandenbroucke, C. Kahlenborn, S. F. Li, S. Shapiro, F. R. Rosendaal, B. C. Tanis, Y. van der Graaf, L. Chasan-Taber, and M. J. Stampfer Oral Contraceptives and the Risk of Myocardial Infarction N. Engl. J. Med., June 6, 2002; 346(23): 1826 - 1829. [Full Text] [PDF]

				L. Chasan-Taber and M. Stampfer Oral Contraceptives and Myocardial Infarction -- The Search for the Smoking Gun N. Engl. J. Med., December 20, 2001; 345(25): 1841 - 1842. [Full Text] [PDF]

				T. B. M. Monster, W. M. T. Janssen, P. E. de Jong, L. T. W. de Jong-van den Berg, and for the Prevention of Renal and Vascular End Stage Oral Contraceptive Use and Hormone Replacement Therapy Are Associated With Microalbuminuria Arch Intern Med, September 10, 2001; 161(16): 2000 - 2005. [Abstract] [Full Text] [PDF]

				M. R. ADAMS, M. S. ANTHONY, J. M. MANNING, D. L. GOLDEN, and J. S. PARKS Low-Dose Contraceptive Estrogen-Progestin and Coronary Artery Atherosclerosis of Monkeys Obstet. Gynecol., August 1, 2000; 96(2): 250 - 255. [Abstract] [Full Text] [PDF]

				L. A. Gillum, S. K. Mamidipudi, and S. C. Johnston Ischemic Stroke Risk With Oral Contraceptives: A Meta-analysis JAMA, July 5, 2000; 284(1): 72 - 78. [Abstract] [Full Text] [PDF]

				J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O'Fallon, and L. J. Melton III Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study Arch Intern Med, March 27, 2000; 160(6): 809 - 815. [Abstract] [Full Text] [PDF]